
On November 9, 2026, the European Medicines Agency (EMA) opened public consultation on its revised draft guideline for medicine risk assessments in human reproduction and breastfeeding, overhauling an 18-year-old framework to incorporate non-animal New Approach Methodologies (NAMs), establish neurodevelopmental monitoring protocols, and reshape clinical trial design for university researchers and pharmaceutical sponsors across Europe.
Regulatory Overhaul: EMA Adopts Rev. 1 for Consultation
The European Medicines Agency released the draft revision, designated EMA/CHMP/PRAC/203927/2005 Rev. 1 and titled “Guideline on risk assessment of medicinal products in human reproduction and breastfeeding: from data to product information,” following adoption by the Committee for Medicinal Products for Human Use (CHMP) and the Pharmacovigilance Risk Assessment Committee (PRAC). The consultation opened on November 9, 2026, and runs through February 28, 2027, marking the first major rewrite in this domain since the original guideline took effect in January 2009.
The revised document establishes modern scientific criteria for evaluating and communicating reproductive safety data across medicine lifecycles. Once finalised in mid-2027, it will replace the 2008 guideline, which focused on translating animal toxicology into product labelling. The revision reflects broader European regulatory modernization, paralleling efforts in the EMA draft guideline on predictive biomarker assays by building clear bridges between preclinical laboratory testing and clinical safety governance.
Key Technical Provisions: NAMs, Neurodevelopment, and Tiered Labeling
The guidance introduces several technical enhancements reconciling non-clinical pharmacology with clinical practice. In non-clinical safety evaluation, the guideline aligns with the International Council for Harmonisation (ICH) S5(R3) standard by embedding New Approach Methodologies (NAMs). Sponsors and academic toxicologists are encouraged to deploy alternative in vitro assays, ex vivo placental and embryonic models, and non-mammalian in vivo systems, such as zebrafish assays, to explore toxicity mechanisms and reduce conventional animal testing.
A second major advancement is a dedicated framework for neurodevelopmental disorders (NDD). Recognizing that prenatal exposure may alter cognitive, motor, language, or social function without visible anatomical malformations, the guideline sets explicit standards for tracking intellectual disabilities, autism spectrum disorder, and ADHD. Because animal models have recognized translational limits for complex cognition, the guideline requires post-marketing human observational studies and registries with multi-year pediatric follow-up, validated developmental scales, and methodological controls for live-birth bias.
In lactation assessment, the draft requires quantification of infant exposure risks. Applicants and clinical investigators must estimate infant daily doses, relative infant dose (RID), and milk-to-plasma concentration ratios. The guidance highlights physiologically based pharmacokinetic (PBPK) modeling to simulate drug transfer into breast milk before or alongside clinical lactation studies. Crucially, detection of a drug in milk does not automatically warrant a contraindication; assessors must balance potential infant exposure against the established nutritional and developmental benefits of breastfeeding.
To communicate these findings clearly, the guideline revamps Section 4.6 (Fertility, pregnancy and lactation) and Section 4.3 (Contraindications) of the Summary of Product Characteristics (SmPC) into a four-tier recommendation hierarchy:
| Tier Level | Standard Recommendation Text | Clinical Context and Regulatory Criteria |
|---|---|---|
| Tier 1: Strict Contraindication | Contraindicated during pregnancy or breastfeeding | Reserved for documented or high-probability risks of major congenital malformations or severe neurodevelopmental harm. |
| Tier 2: Restricted Use | Should not be used unless clinically essential | Applied where potential serious risks cannot be excluded, but maternal health demands therapy without safer alternatives. |
| Tier 3: Permissible Use | Use may be considered | Employed when available clinical and non-clinical data are limited but show no signal of serious pregnancy or infant risks. |
| Tier 4: Unrestricted Use | Can be used during pregnancy or lactation | Concluded when extensive human and non-clinical evidence demonstrates that adverse developmental risks are unlikely. |
Background and Transatlantic Regulatory Alignment
For nearly two decades, European product information for pregnant and nursing individuals relied heavily on defensive boilerplate language, stating treatments were “not recommended” even when pharmacology suggested minimal risk. This risk-averse default often led clinicians and patients to abruptly discontinue medications for chronic illnesses—such as epilepsy, asthma, autoimmune conditions, and depression—triggering maternal disease flare-ups that posed greater harm than the medicines themselves.
The revision aligns Europe with a broader international shift toward nuanced risk communication. In the United States, the Food and Drug Administration eliminated its letter-grade pregnancy categories (A, B, C, D, X) in 2015 under the Pregnancy and Lactation Labeling Rule (PLLR), adopting narrative summaries of clinical risks and data. While the European Union maintains standardized SmPC statements, Rev. 1 introduces structured, evidence-based tiers. For developers navigating international submissions, examining EMA vs FDA regulatory pathways shows how both authorities are moving toward quantitative risk characterization and transparent benefit-risk communication.
Regulatory and Clinical Research Community Reaction
The consultation draft has drawn strong backing from regulatory specialists and clinical investigators. Analysis in the Regulatory Affairs Professionals Society (RAPS) Euro Roundup highlighted that the guidance signals an institutional paradigm shift, moving from reflexively excluding pregnant and lactating individuals to protecting them through deliberate evidence generation.
Reporting from Citeline’s Pink Sheet noted that the guideline resolves persistent ambiguity for clinical trial sponsors. By creating standardized SmPC text structures, the EMA provides biopharmaceutical developers with actionable templates that connect preclinical safety packages with post-market pharmacovigilance expectations.
Compliance analysts at the PROCIDA-i regulatory consultancy welcomed the formal inclusion of New Approach Methodologies. Experts noted that recognizing in vitro and ex vivo assays under EU guidance gives researchers a legitimate regulatory pathway to reduce animal testing while improving mechanistic safety profiling.
Implications for University Researchers, IRBs, and Trial Sponsors
The revised guideline carries practical consequences for academic medical centers, university investigators, institutional review boards (IRBs), and translational research offices:
- Translational and Non-Clinical Testing: Academic discovery teams and spin-outs must modernize toxicology workflows. Early dossiers should incorporate validated in vitro assays and computational screening to establish weight-of-evidence packages before initiating mammalian reproductive studies.
- Clinical Protocol Design: Investigators evaluating an investigational medicinal product (IMP) must ensure eligibility criteria and contraception rules match demonstrated pharmacological risks, defining specific contraceptive windows based on compound half-life rather than applying default exclusion periods.
- Post-Authorization Pharmacovigilance: Research offices managing registries or post-authorization safety studies (PASS) must update protocols to meet Good Pharmacovigilance Practices (GVP) standards, particularly GVP Module XVI on embryo-fetal risk management. Studies must track multi-year pediatric milestones and control for live-birth bias.
- Academic Technology Transfer: University spin-outs preparing regulatory dossiers for clinical trial authorizations (CTA) or marketing applications in the EU must align their draft SmPC Section 4.6 proposals with the four-tier statement framework.
Consultation Timelines and Implementation Roadmap
Public consultation on EMA/CHMP/PRAC/203927/2005 Rev. 1 is open through February 28, 2027. Researchers, institutional ethics committees, professional societies, and pharmaceutical developers can submit comments via the European Commission EUSurvey portal.
Following consultation closure, CHMP and PRAC working groups will review feedback in spring 2027, targeting final guideline adoption by mid-2027. Once implemented, the guideline will take effect across all 27 EU Member States and EEA countries, replacing EMEA/CHMP/203927/2005 for all subsequent marketing authorizations and variation applications.
Sources
- European Medicines Agency: Draft Guideline on Risk Assessment of Medicinal Products in Human Reproduction and Breastfeeding: From Data to Product Information (EMA/CHMP/PRAC/203927/2005 Rev.1), checked 2026-11-20
- Citeline: EMA Revamps 18-Year-Old Pregnancy, Lactation Risk Assessment Guide – Includes Updated Labeling Text, checked 2026-11-20
- Regulatory Affairs Professionals Society (RAPS): Euro Roundup: EMA Floats Change in Paradigm for Pregnant and Breastfeeding Patients in Clinical Trials, checked 2026-11-20
- PROCIDA-i: EMA Consults on Revising the Guideline on Risk Assessment of Medicinal Products in Human Reproduction and Breastfeeding, checked 2026-11-20







